2. Search Result
Search Result
Results for "

Aminoacyl-tRNA+Synthetase

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

16

Peptides

1

Inhibitory Antibodies

1

Natural
Products

1

Recombinant Proteins

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P4070
    Insulin icodec

    		Insulin Receptor Metabolic Disease
    Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .
    Insulin icodec
  • HY-108939
    Aminoacyl tRNA synthetase-IN-1

    IleSA

    		 Bacterial Aminoacyl-tRNA Synthetase Infection
    Aminoacyl tRNA synthetase-IN-1 (IleSA) is an inhibitor of bacterial aminoacyl-tRNA synthetase (aaRS). Aminoacyl tRNA synthetase-IN-1 is applicable to studies on bacterial infections .
    Aminoacyl tRNA synthetase-IN-1
  • HY-112861
    Gln-AMS
    3 Publications Verification

    		 Aminoacyl-tRNA Synthetase Bacterial Infection
    Gln-AMS is an aminoacyl-tRNA synthetases (AARS) inhibitor, which binds the A-domain within the NRPS enzymes.
    Gln-AMS
  • HY-P5362
    NODAGA-LM3

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Neurological Disease Cancer
    NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .
    NODAGA-LM3
  • HY-P2336A
    CCZ01048 TFA
    3 Publications Verification

    		 Melanocortin Receptor Cancer
    CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .
    CCZ01048 TFA
  • HY-P990782
    Efzofitimod

    		Aminoacyl-tRNA Synthetase Inflammation/Immunology
    Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .
    Efzofitimod
  • HY-112861A
    Gln-AMS TFA
    3 Publications Verification

    		 Aminoacyl-tRNA Synthetase Bacterial Infection
    Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor. Gln-AMS inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 µM.
    Gln-AMS TFA
  • HY-117938
    T-3861174

    		Aminoacyl-tRNA Synthetase Cancer
    T-3861174 is an inhibitor of prolyl-tRNA synthetase (PRS, Aminoacyl-tRNA Synthetase) without completely inhibiting its translation process. T-3861174 activates the GCN2-ATF4 pathway and induces death in multiple tumor cell lines, including SK-MEL-2. T-3861174 demonstrated significant antitumor activity in multiple xenograft models without significantly affecting body weight .
    T-3861174
  • HY-147643
    Aminoacyl tRNA synthetase-IN-2

    		Aminoacyl-tRNA Synthetase Infection
    Aminoacyl tRNA synthetase-IN-2 (Compound 14) is an aminoacyl-tRNA synthetase (aaRS) inhibitor. Aminoacyl tRNA synthetase-IN-2 can be used for development of a new family of antibiotics .
    Aminoacyl tRNA synthetase-IN-2
  • HY-P10341
    ZP3022

    		GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022
  • HY-128189
    Aminoacyl tRNA synthetase-IN-4

    		Aminoacyl-tRNA Synthetase Fungal Infection
    Aminoacyl tRNA synthetase-IN-4 (Compound 1l) is an inhibitor of Aminoacyl tRNA synthetase, with an IC50 of 0.026 μM for C.albicans prolyl-tRNA synthetase. Aminoacyl tRNA synthetase-IN-4 can be used for antifungal research .
    Aminoacyl tRNA synthetase-IN-4
  • HY-161800
    Aminoacyl tRNA synthetase-IN-3

    		Aminoacyl-tRNA Synthetase Infection
    Aminoacyl tRNA synthetase-IN-3 (compound 36K3) is an inhibitor of lysine tRNA synthetase (PfLysRS) from Plasmodium falciparum (IC50=59.2 nM), which inhibits the activity of PfLysRS by occupying the ATP binding site and L-lysine binding site of PfLysRS. Aminoacyl tRNA synthetase-IN-3 can be used in the development of antimalarial drugs .
    Aminoacyl tRNA synthetase-IN-3
  • HY-108939R
    Aminoacyl tRNA synthetase-IN-1 (Standard)

    IleSA (Standard)

    		 Reference Standards Bacterial Aminoacyl-tRNA Synthetase Infection
    Aminoacyl tRNA synthetase-IN-1 (Standard) is the analytical standard of Aminoacyl tRNA synthetase-IN-1 (HY-108939). This product is intended for research and analytical applications. Aminoacyl tRNA synthetase-IN-1 is a bacterial aminoacyl tRNA synthetase (aaRS) inhibitor. Aminoacyl tRNA synthetase-IN-1 has inhibitory activity against S. aureus, E. faecalis and E.coli .
    Aminoacyl tRNA synthetase-IN-1 (Standard)
  • HY-P11004
    A3-APO

    		Bacterial Antibiotic Infection
    A3-APO is an antimicrobial peptide. A3-APO has a significant antimicrobial activity by a dual mode of action with both membrane disintegration and intracellular target inhibition. A3-APO can deactivate bacterial toxins and increase the expression of anti-inflammatory cytokines (such as IL-4 and IL-10), without antimicrobial resistance. A3-APO accelerates burn wounds healing in mice infection model of Acinetobacter baumannii and Staphylococcus aureus .
    A3-APO
  • HY-P10472
    Azaline B

    		GnRH Receptor Endocrinology
    Azaline B is an antagonist for gonadotropin-releasing hormone (GnRH) with IC50 of 1.37 nM, Azaline B can be used in research of sex hormone-related pathological states, ovulation induction and male contraception .
    Azaline B
  • HY-P4757
    N1-Glutathionyl-spermidine disulfide

    		Parasite Others
    N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
    N1-Glutathionyl-spermidine disulfide
  • HY-P11243
    EphA4 agonist compound 23

    		Ephrin Receptor Neurological Disease
    EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .
    EphA4 agonist compound 23
  • HY-P2434
    AP102

    		Somatostatin Receptor Neurological Disease Metabolic Disease Cancer
    AP102 is a dual SSTR2/SSTR5-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to SSTR2 and SSTR5 (IC50: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .
    AP102
  • HY-P5362A
    NODAGA-LM3 TFA

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 TFA can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .
    NODAGA-LM3 TFA
  • HY-105168
    TAK 044

    		Endothelin Receptor Cardiovascular Disease
    TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .
    TAK 044
  • HY-P2075
    EMD 55068

    		Renin Endocrinology
    EMD 55068 is a renin antagonist. EMD 55068 inhibits the uptake of taurocholate .
    EMD 55068
  • HY-P10876
    mcK6A1

    		Amyloid-β Neurological Disease
    mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
    mcK6A1
  • HY-P11488
    JR11-PEG3-DOTA-PSMA-03

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA Cancer
    JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
    JR11-PEG3-DOTA-PSMA-03
  • HY-P11485
    JR11-PEG3-HBED-CC-PSMA-03

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA Cancer
    JR11-PEG3-HBED-CC-PSMA-03 (Compound 1) is an RDC-related compound containing the chelating agent HBED-CC, the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-HBED-CC-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 59.2 nM, 57.0 nM, respectively. JR11-PEG3-HBED-CC-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-HBED-CC-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
    JR11-PEG3-HBED-CC-PSMA-03

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: